Bayer (BAYN) PT Set at €84.00 by Kepler Capital Markets

Kepler Capital Markets set a €84.00 ($97.67) target price on Bayer (FRA:BAYN) in a research note issued to investors on Thursday morning. The firm currently has a buy rating on the healthcare company’s stock.

A number of other analysts have also recently issued reports on BAYN. HSBC set a €104.00 ($120.93) target price on shares of Bayer and gave the company a neutral rating in a research note on Monday, August 13th. Goldman Sachs Group set a €116.00 ($134.88) target price on shares of Bayer and gave the company a buy rating in a research note on Monday, August 13th. Independent Research set a €95.00 ($110.47) target price on shares of Bayer and gave the company a neutral rating in a research note on Monday, August 13th. Barclays set a €110.00 ($127.91) target price on shares of Bayer and gave the company a buy rating in a research note on Monday, August 13th. Finally, Commerzbank set a €111.00 ($129.07) target price on shares of Bayer and gave the company a buy rating in a research note on Monday, August 13th. Six equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of €90.80 ($105.58).

FRA BAYN opened at €63.43 ($73.76) on Thursday. Bayer has a 12-month low of €91.58 ($106.49) and a 12-month high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Article: Derivative

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit